<SEC-DOCUMENT>0001104659-11-046786.txt : 20110815
<SEC-HEADER>0001104659-11-046786.hdr.sgml : 20110815
<ACCEPTANCE-DATETIME>20110815085547
ACCESSION NUMBER:		0001104659-11-046786
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110815
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110815
DATE AS OF CHANGE:		20110815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO KEY INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001019034
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER COMMUNICATIONS EQUIPMENT [3576]
		IRS NUMBER:				411761861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13463
		FILM NUMBER:		111033290

	BUSINESS ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719
		BUSINESS PHONE:		6516870414

	MAIL ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SAC TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19961115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a11-24394_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>August&nbsp;15, 2011</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">BIO-key International,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-13463</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">41-1741861</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3349 Highway 138, Building D, Suite&nbsp;B</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Wall, NJ 07719</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(732)&nbsp;359-1100</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2 below):</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105579\11-24394-1\task4829492\24394-1-ba.htm',USER='105579',CD='Aug 13 01:46 2011' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Results of Operations and Financial Condition.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;15, 2011, BIO-key International,&nbsp;Inc. (the &#147;Company&#148;) issued a press release announcing its financial results for its second quarter ended June&nbsp;30, 2011 which is included as an exhibit to a Current Report on Form&nbsp;8-K.&nbsp;A copy of the press release issued by the Company on August&nbsp;15, 2011 is attached as Exhibit&nbsp;99.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information, including the exhibit attached hereto, in this Current Report on Form&nbsp;8-K shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements, Pro Forma Financial Information and Exhibit.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Press Release, dated August&nbsp;15, 2011, issued by </font><font size="2" style="font-size:10.0pt;">the Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_014234_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105579\11-24394-1\task4829492\24394-1-ba.htm',USER='105579',CD='Aug 13 01:46 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-KEY INTERNATIONAL,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;15, 2011</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Cecilia C. Welch</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cecilia   C. Welch</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_014348_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105579\11-24394-1\task4829492\24394-1-ba.htm',USER='105579',CD='Aug 13 01:46 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:88.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   Release, dated August&nbsp;15, 2011,   issued by the Company.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_014430_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105579\11-24394-1\task4829492\24394-1-ba.htm',USER='105579',CD='Aug 13 01:46 2011' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a11-24394_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="66%" rowspan="9" valign="top" style="padding:0in 0in 0in 0in;width:66.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman"><img width="192" height="144" src="g243941mmi001.jpg"></font></p>    </td>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>    </td>   </tr>
<tr>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>    </td>   </tr>
<tr>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>    </td>   </tr>
<tr>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>    </td>   </tr>
<tr>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">NEWS RELEASE</font></i></b></p>    </td>   </tr>
<tr>
<td width="34%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:34.0%;">
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contacts:</font></p>    </td>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.58%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key   International,&nbsp;Inc.</font></u></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott   Mahnken</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">732-359-1113</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIO-key International Inc.&#174; Reports 2011 Second Quarter Financial Results</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Extinguishes Debt Leaving Clean Balance Sheet and Only Common Shares on its Capital Table</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Wall, NJ, August&nbsp;15, 2011</font></b><font size="2" style="font-size:10.0pt;"> &#151; BIO-key International,&nbsp;Inc. (OTC Bulletin Board: BKYI), a leader in fingerprint biometric identification solutions, today reported financial results for the second quarter ended June&nbsp;30, 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue for the three months ended June&nbsp;30, 2011 was approximately $1 million, representing an overall decrease of 31% from the $1.4 million reported for the quarter ended June&nbsp;30, 2010. The decrease was primarily attributed to an order received in 2010 from a new healthcare customer, specifically in the blood bank sector. Blood banks have contributed significant revenue in the past, yet due to a spending freeze in the blood bank industry which is under consolidation, most of our prospects are being asked to curtail purchases until late 2011 or early 2012. Embedded in the overall decrease, the Company reported an increase in service revenues of approximately 34%, which was driven by a mix of some new accounts and renewed maintenance agreements from legacy customers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key&#146;s gross margin for the second quarter of 2011 was 70% compared to 93% for the same period in 2010, due to the costs associated with the increase in third party hardware revenue.&nbsp; Operating expenses for the second quarter of 2011 decreased 21% to approximately $926,000 compared to $1,173,000 in the comparable quarter ended June&nbsp;30, 2010.&nbsp;Operating loss for the second quarter of 2011 was ($234,039), compared to operating income of $156,633 reported in the quarter ended June&nbsp;30, 2010.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss for the three months ended June&nbsp;30, 2011 was ($594,224) compared to net income of $234,766 for the comparable period in 2010.&#160; Net income for the 2010 period included approximately $191,000 in income related to derivative and fair value adjustments no longer applicable in 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the quarter,&nbsp;InterAct911 Mobile Systems,&nbsp;Inc. exercised its option to prepay the balance due of $3,222,000 under the Note Receivable issued to BIO-key nearly twenty months ahead of the scheduled final maturity date in December&nbsp;2012. As a result, BIO-key exercised its prepayment option and paid the outstanding debt owed to its principal investor on its Secured Promissory Note in the amount of $3,157,759.&#160; At June&nbsp;30, 2011, the Company owes $346,428 to another investor under an outstanding Secured</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\skris\11-24394-1\task4829573\24394-1-mm.htm',USER='105340',CD='Aug 13 02:22 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Promissory Note. In consideration for the early payment from InterAct911, BIO-key accepted a $150,000 discount on the principal amount due on the Note Receivable and our Secured Promissory Note holders agreed to absorb $50,000 of the discount with the remainder borne by the Company.&#160; The net discount of $100,000 for the Note Receivable and Secured Promissory Notes is included as interest expense in the three and six months ended June&nbsp;30, 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The transactions with Interact911 and Secured Promissory Note holders over the past 3 quarters, as well as the expiration of warrants subsequent to the close of the quarter have resulted in a reduction of our fully diluted share count from approximately 111 million shares to approximately 92 million shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are starting to witness some very interesting trends in our industry.&#160; During the second quarter of 2011, we secured a contract to install BIO-key software with a fifth hospital in the state of Ohio and have inquiries from others,&#148; said Michael DePasquale, BIO-key&#146;s Chief Executive Officer.&#160; &#147;Additionally, we are experiencing a higher demand for mobile biometric technology solutions in healthcare and government.&#160; Moving forward we believe that offering a fingerprint biometric solution for the Apple iPad and iPhone would generate significant interest with decision makers in healthcare, commercial enterprise and government agencies. With our pending acquisition of SIC Biometrics Inc., which we are also announcing today, we believe that BIO-key will be in a first mover position, as evidenced by the strong order rate at the early introduction of the production version of their iFMID snap on fingerprint scanner for Apple iSeries&nbsp;products.&#160; Just 2 weeks ago SIC secured a large order valued at over $1.5M USD from Canada&#146;s largest healthcare institution to provide strong, secure, convenient access to information by clinicians and administrators via their iPhone and iPad.&#148;&#160; With the explosive growth forecast for Apple iPad and iPhone devices BIO-key is very well positioned to meet the demands for mobile enterprise and consumer security,&#148; stated DePasquale.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Six Month Comparisons</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue for the six months ended June&nbsp;30, 2011 was $2.389 million representing a 1% decrease from the $2.409 million reported for the same period in 2010.&#160; Although the revenue amounts are similar, the product mix varied with an increase in third party hardware revenue to approximately $530,000, license revenue of $1.5 million and service revenue of $309,000 for the six months ended June&nbsp;30, 2011 compared with third party hardware revenue of approximately $173,000, license revenue of $2.5 million and service revenue of $204,000 for the same period in 2010.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gross margin for the six months ended June&nbsp;30, 2011 was approximately $2.0 million representing a 10% decrease from the same period in 2010 of $2.2 million. Operating expenses for the first six months of 2011 also decreased 10% to approximately $1,932,000 compared to $2,157,000 in the comparable period ended June&nbsp;30, 2010.&nbsp;The decline in operating expenses were primarily related to lower legal, accounting and referral fee expenses, offset by an increase in R&amp;D expenses. Operating income for the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\skris\11-24394-1\task4829573\24394-1-mm.htm',USER='105340',CD='Aug 13 02:22 2011' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">six months ended June&nbsp;30, 2011 was $49,948, compared to operating income of $37,899 reported for the same period in 2010.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss for the six months of 2011 was ($354,154) compared to net income of approximately $1.2 million for the comparable period in 2010.&#160; Net income for the 2010 period included approximately $977,000 in income related to derivative and fair value adjustments and $426,269 in income from discontinued operations, both no longer applicable in 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liquidity and Capital Resources</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consolidated cash, cash equivalents and accounts receivables totaled over $1.7 million on June&nbsp;30, 2011 compared to $1.4 million as of December&nbsp;31, 2010.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Highlights for the second quarter included the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Nationwide Children&#146;s Hospital, one of the largest pediatric hospitals and research institutes in the U.S. implemented Phase 2 of the installation of BIO-key software; expanding the footprint from 300 to 2,500 finger print readers and expanding from 1650 to 6500 users.&#160; Part&nbsp;of the expansion includes future deployment at Nationwide Children&#146;s new state of the art facility scheduled to open in January&nbsp;2012.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Received Phase 2 orders for an ongoing international project to register SIM card users for an international client.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Dayton Children&#146;s has a staff of over 350 physicians and 1,300 employees and volunteers.&#160; During Q2 Dayton Children&#146;s in Ohio contracted with BIO-key to deploy strong identification and authentication for their staff members to comply with Ohio Board of Pharmacy Positive ID requirements inside their Epic deployment.&#160; A total of 1800 users and 575 Lumidigm fingerprint readers were purchased from BIO-key.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Purchase orders from McKesson, ChoicePoint/ LexisNexis, Educational Biometric Technology,&nbsp;Identimetrics&nbsp;&amp; Genesis Healthcare</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Received a follow up order from ITxM one of the nation&#146;s foremost organizations specializing in transfusion medicine, as they prepare to deploy their BIO-key-based Donor identification platform to their locations.&nbsp; They will be using the built-in fingerprint scanners in several hundred Panasonic H1 tablets in conjunction with existing laptops to enroll and identify over 1.6 million donors who visit their blood centers.</font></p>
<p align="center" style="margin:0in 0in .0001pt .5in;text-align:center;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\skris\11-24394-1\task4829573\24394-1-mm.htm',USER='105340',CD='Aug 13 02:22 2011' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Renewed our partnership agreement with CA Technologies allowing BIO-key to update and make available to all CA customers who have deployed Siteminder&#160; .&#160; BIO-key has integrated WEB-key into Siteminder enabling all of CA&#146;s customers to immediately take advantage of our award winning biometric authentication through a simple configuration in their Siteminder deployments.&#160; BIO-key continues to maintain and advance our relationship with CA and its customers.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">WEB-key 3.4, BIO-key&#146;s client server authentication solution, now provides support for clients running on iOS platforms like the iPhone, iPad and iPod, utilizing fingerprint sensors from various providers.&nbsp; The WEB-key client on iOS is compatible with those of Windows and other platforms providing for a single enrollment across multiple systems and activities.&nbsp; The client provides security and&nbsp;convenience for easy to use authentication.&nbsp; Additional client support for Android Operating Systems is also now available.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conference Call Details</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key has scheduled a call for Monday August&nbsp;15</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">&#160;at 10:00&nbsp;a.m. Eastern Time to discuss 2011 second quarter results.&nbsp; To access the conference call live, dial 877-344-7529 and ask for the BIO-key call at least 10 minutes prior to the start time.&nbsp; The conference call will also be broadcast live over the Internet by logging onto <b>www.bio-key.com</b>. A telephonic replay of the conference call will be available through September&nbsp;14, 2011 and may be accessed by dialing 412-317-0088&nbsp;and using the pass code 452169#. A streaming audio replay of the webcast will be available shortly after the call on the Company&#146;s website (www.bio-key.com) for a period of thirty days.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About BIO-key</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key International,&nbsp;Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers.&nbsp;BIO-key&#146;s award winning, high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications. Our solutions are used in local embedded OEM products as well as some of the world&#146;s largest identification deployments to improve security, guarantee identity, and help reduce identity theft.&nbsp;&nbsp;BIO-key&#146;s technology is offered directly or by market leading partners around the world. (<b>http://www.bio-key.com</b>)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIO-key Safe Harbor Statement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain statements contained in this press release may be construed as &#147;forward-looking statements&#148; as defined in the Private Securities Litigation Reform Act of 1995 (the &#147;Act&#148;).&nbsp; The words &#147;estimate,&#148; &#147;project,&#148; &#147;intends,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;believes&#148; and similar expressions are intended to identify forward-looking statements.&nbsp; Such forward-looking statements are made based on management&#146;s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the &#147;safe-harbor&#148; provisions of the Act.&nbsp; These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements.&nbsp; These risks and uncertainties include, without limitation, our</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\skris\11-24394-1\task4829573\24394-1-mm.htm',USER='105340',CD='Aug 13 02:22 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">history of losses and limited revenue, our ability to develop new products and evolve existing ones, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, our ability to attract and retain key personnel and our ability to complete the proposed acquisition of S.I.C. Biometrics Inc. as currently planned.&nbsp; For a more complete description of these and other risk factors that may affect the future performance of BIO-key International,&nbsp;Inc., see &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2010 and its other filings with the Securities and Exchange Commission.&nbsp; Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.&nbsp; The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\skris\11-24394-1\task4829573\24394-1-mm.htm',USER='105340',CD='Aug 13 02:22 2011' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g243941mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g243941mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`"0`,`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V7-&:**`#
M-&:*0D`$G@"@!<T9KD-?^(^DZ2S06A^WW*\;8CA%/NW^&:\]U?QUK^L%E>[-
MK"?^65O\HQ[GJ:PGB(1TW.^AE]:KK:R\SV+4->TG2A_IVH6\!_NLXW?EUKG;
MOXH^'K<D0?:;HC_GG'@?FV*\=)R2S')/4D\UHZ=X?UC5L?8=.GF4_P`>W"_F
M>*YGB9R^%'I1RNA35ZLOT.[F^+L7_+#1I#[R3`?R!J#_`(6[<?\`0&C_`._Y
M_P`*S[/X5Z[.`;F>UM0>Q8N?TX_6M:'X0IC]_K3Y](X`/YFFGB&2UEL-'K]X
MR/XO/G][HHQ_L3_XBM&U^+.CR$"YLKN#W`5Q^AJ$?"/3\<ZK=D_[BU!-\(8\
M?N-:<'TD@!_D:I?6$9/^S9=U]YU5AXU\.ZD0L&IQ*Y_@E_=G]:W%=74,I#*>
MA!R#7DEY\*=:A!-O<VER/[I)0_KQ68L/C#P@^]$O+6-3SC]Y$?J.15^VG'XX
MF;P5"I_!J+T?]?H>WYHS7G6@_%2&4K#K<`A)X^T0C*_BO4?AFN_M;J"]MTN+
M:9)HG&5=&R#6\*D9[,X*V'J47::)LT9HHJS`,T9HHH`,T9HHH`,T44"@`HHK
M+\0:]:>'M,>]NVR>D<8/S2-Z"DVDKLJ,7)J,=R76-:L-#L6N[^81H.%'5G/H
M!W->1>)O'6I>(&:"(M:6/:%&^9Q_M'O].E9.MZY?:_J#7E[)D](XQ]V-?051
MBBDGE2*)&DD<[511DL?05YU6NYNT=CZ3"8"%%<]367X(9P!Z"NE\.^!=6\0!
M9MOV2T/_`"WE'WA_LKW_`)5V'A+X<P62QWVMHL]S]Y;<\I']?[Q_2N]``&!P
M!T%72PU]9F&*S2SY:/W_`.1S6B^`M"T8*_V;[7<#_EK<?-S[#H*Z4`*````.
M@%+17;&*BK)'ASJ3J.\W<****H@**@N[RVL8#/=W$<$2]7D8**Y/4/BCH-HQ
M2V$]ZP[QKM7\S42G&.[-:=&I5^"-SLZ3J,=J\X_X6Q-.W^B:!)*/^NI8_HM6
M(_B=<Q\WGAJ\C7NR$_U45'MX=SH>`Q"WC^*-W6_`NAZT&=K86UP?^6UOA3GW
M'0UQ,FE^)_AY<M=V3_:]/)S)M!*$?[2_PGW%=GI?Q!\/:HXB%V;68\>7<C9S
M]>GZUTGRR+V96'U!%)PA/WHO7R*C7K4/<JJZ[/\`0Q_#?BBP\2V?G6K;)4'[
MV!C\R'^H]ZVJX/Q#X-N-,O/[?\+?N+J(EI+9/NN.^T?^R]^U=%X8\16_B33!
M<QCRYD.V>$GF-O\`#TJH2=^66YE6I1Y?:4OA_%>IM4445J<H4444`%`HH%`$
M5S<16EM)<3N(XHE+NQZ`"O"O%'B*?Q)J[W3Y6!,K!$?X%]?J>IKMOBGKQBMX
M=$@?YIAYD^/[H/"_B>?PKS"O/Q-2[Y$?0Y7AE&/MI;O84`D@`$D\`#O7K_@3
MP8FBVZZC?Q@ZA*N0#_RP4]A[^OY5S/PS\-KJ&H-J]U'N@M&Q$".&D]?P_F:]
M&O?$>AZ:=M[K%E;L.JR3J#^6:O#4OMLRS/%N_L8/U_R-+%+619^+?#FH2B&T
MURPFD/`1;A<G\,UKYQUKM/#"BJ1UG2@<'4[//_7=?\:GM[RUNPQM;F&<+][R
MI`V/RH`FKE?&/C6#PW']F@59]0D7*QD_+&/[S?X5U)KR'6O#=M_PE,]QK'B7
M38;268R/(]RHEVY^[M]<<>E957-+W#KPD:,IWK.R7XE*PTGQ#X^OS<3SLT2M
MAIY?]7'[*OK["O0M'^'F@Z6JM-;_`&Z<=9+CD9]EZ"M70[_09K..UT2]LYH8
MEPJ6\JM@?0&M6IA1C'5ZLNOCJE3W8>['LAD4$4"!(8DC4=%10!^E/HHK<X3.
MU'P_I&K1E+[3H)L_Q%`&'XCFL)='U7PF?.T:674-.',FGS-ET'K&W]#74W-U
M;V<#3W4\<$2_>DD<*H_$TL$\-U`D]O*DL4@W)(C!E8>H(J'!/7J:QK2BN5ZK
ML0:?J%MJEE'>6DF^*0<'&"#W!'8CTKE=?L7\+ZROBG3D/V=R$U*!!PRD_?`]
M1_GO6TUL-(UP7,`VVNH/LN$'19?X7'U^Z??%:\T,=Q`\,R!XY%*LIZ$'J*37
M,K/=%1FJ<KKX7^0L,J3PI-$X>.10RL.A!Z&GUSOA+S+!;S0)F+-ILN(6/5H6
MY0_AR/PKHJJ+NKF=2/+)H****H@*!10*`/GG5]1EU75[J^E))FE9@#_"N>!^
M55%1I'5$4LS$!0.Y/2O5=;^%UG?W;W6GWC6;2,6>-DWIDG/'0CZ58\,_#FTT
M6\6^O+G[9<1G,8V;40^N.YKS?J]1RU/IEF6'C2]W?L<S\1M#UG1/AY9+I>H?
M9K.R4?;HD8H\SL1SD=1DGBO./AYX1B\:^(WL+FZ>"&.%II&0`LV"!@9^M>W?
M%L?\6VU/_MG_`.C%KRKX,ZE9:/XDU"_U&Y2VMHK!M\CG@9=`*]%*RLCYN4G)
MN3W9H^/_`(16WAK09-9TF]GFCMR/.BGP2%)QD$`="1Q6A\'O%=WK(O/"6K32
M7$#VS&!V8[U7HR;NN,'(],4_XE_%+1-5\-SZ)HDKW4ET0LDVPJB*""<9Y).*
M;\$O!]];7DOB2^A>"%H3%:JXP9-Q!+8],#`]<TR3@/B%X;L_"GBV?2K&25X$
M1'4RD%AN&<9%>P_"GPMIF@^&(?$*S2^??VH>=I'PB*"3P/;U->:_&G_DHUS_
M`-<(O_0:[/6=4DTO]GVP$3;7NX([?(]&)+?H"/QH`Y#QS\2=6\7:H=,T>2:#
M3C)Y<44)(>X.<`MCGGLM='HGP&\^Q2;7-5DAN'&3#;H#L]BQZGZ"N:^"^F)J
M'CV.>5`RV4#SC/\`>X4?^A9_"OHR@#YX\:?"[5/!,(UG3+Z2ZM(F&Z5`8Y8#
MV)P>F>XKL_A1\2KC79?[!UN7S+U4+6]P>LP'56_V@.<]^:]+U"RBU+3KFQG4
M-%<1-&X/H1BOD_3[J?P]XE@N8V*S6-T#D?[+8/Y\T`?7-%-C<21K(O1@"/QI
MU`'SS\9=,U73O$:37VK27MO>EY+>)B0(%!^[CIWZBO6?A82?AOH^?^>;_P#H
M;5Y]^T!_R$=%_P"N,O\`-:Z#PSXVTKP9\,/#\NIK<,+E9%001[NCG.<D`=:`
M/1[RV%W;-"3MS@@^A!R#^8J>N%T3XN^'->U>WTNTAOUGN6VH7A&W/OACBM[Q
M/XPT7PE:+/JMSM:3/EPH-TDGT']3Q0`^YB^S^*K*[7@74#V\GN1\Z_R:MFO)
MI?CCX>NKNW\W2]11(9=ZNI0GH1R,^A-=%J'Q<\*Z?8VEXL]Q=QW8.WR(\E",
M9#`D8//2DE8J3ND=O17`:=\9O#&IZE;V$,.H+)<2+&A:$8!)P,X8FM#Q1\3-
M"\):H--U&.\><QB3]S$"H!Z<DBF2=?0*X_1?B;H6O6ES/91W8-L5#))$%+9!
M/!SC@*2?2NATK5X=51S&C1NGWD;!XR1D$=1D$?4&@"_1110!QOQ:_P"2;:I_
MVS_]&+7DWP>T:PU_7=2TW4H!/;2V)W(21R'0@@CH0:].^,>IV5KX$N[&:YC2
MYN]GDQ$_,^'4G`]`*\[^!4\<7C6XC>15:6R94!.-QW*<#\*`.B\;?!K2+30;
MG4=!:>&>TC,K0R/O610,D#/(.*P/A)X[U"QU^VT"]N'GT^[/EQ+(V3"_\.TG
ML>F/>O7?'.O6>@>$[^>[E57D@>*&,GF1V!``'XU\_?#33)]4\?:4D*%E@F$\
MC#^%5YR?T'XT`:GQH_Y*+<_]<(O_`$&ND\5P/+\`="D49$+0LWT.X?S(KFOC
M1_R46Y_ZX1?^@UZMX?T6+Q%\&[+292%%S8!58_PMG*G\"!0!YU\!YTC\8WD+
M'#2V3;?P937OU?*VB7]_X!\;17%U`Z3V,Q2>$\%E/#`?4'(/TKZ8T;7]+U^Q
M2\TR]BN(G&?E8;E]F'4&@#0)"@DG`')-?(6HM]MUVZ>+D3W+E,=\L<?SKZ`^
M)GQ`L/#^AW.GV=U'-JES&8TCC8$P@\%FQTXZ#UKRWX3^$9?$7BF*]FB)T_3W
M$LK$<,XY5/SY/L*`/2M>^+6F^$=4.ASZ;=7$MK%&)'1E`W%0<<_6LS_A?^E?
M]`.\_P"_JUWVI^#?#>LWK7NI:/;7-PP`:1UY('3-5/\`A6_@W_H7K/\`[Y/^
M-`'E'QDU>'7K;PUJMNCI%=6LDBJ_5<D<&LF3Q7-K7A+0O`VG[(59@ES--@`N
M9"5`/91D$G_)W_CM:V]C<Z#:6L*0P0VTBQQH,!0"N`*YO5?`TD7P_P!*\5V"
MNZ2(1>)G.P[R`X]N`#Z4`>\^$O!^F>$=)BM+2)&F`S-<LHWR-W.>P]!7S_JE
MW<^._B2$FE;;=WHMXQG_`%<6[``_#GZUZM\)O'W_``D6G#1-3ESJ5JGR.QYG
MC'?_`'AW_/UKQV]M'\,^.YK:],L*VUV0[Q\,(R?O+[[3D4`>D_$S6O!6F>&)
M/#&FVEM/>IM6/[.@_P!&(/)9_P"][=>>:I?"[P'J&H:/JW]L6K0:=J-L(X%E
M7YC)GB10>1CU[YKK_!OPT\*:+;QZNLZ:N[#S([N;'EJ.Q"]!]3^E;ND^/-`U
MOQ%/H6G7+7%Q`A<R*N8VQ@$!N^,B@#P[X?W[>#?B0EKJ4:J#*UG.7'W"3@,#
MVY`Y]#7;_&Z]^W7&C^&;.-)+RYE$A^4%@"=J#/49))_"L3XX^&_L&NV^OP)M
MBOALE([2J.#^*_R-2?"Z*]\8^.Y?$NKL)?[-@4!B,#?MVK^@)^M`'J5OX/L[
M7PS::-;;8?LR`>8$SYAVX;<.^[)K0T?1QI:N6D5W8!55%VI&@)(51DG&6/4U
MS6I_%'2+*[:WMK>>]"'#21D*I/L3UK9\-^+]-\3>8EKYD4\8W/#*,,!ZC'!%
M9JK!NR9T2PU:$.>478WJ***T.<YGQCX#TGQK!$+\RPSP`B*>(_,H/4$'@BO.
M;GX!W\4V_3_$$)`.5,L+(P_$$U[96;XCD>+PSJDL3LCI9RLK*<%2$."#0!Y/
M#\"=5NIU?5?$<;*.I1&D;'MN(KT3P]X$TGPOH]Q8:698YKJ,I+>D@S$XP"#V
MQG(`KAM0U7Q#%IO@>YTJYFFNAI\ES-"TC'[4$1&96_O$C.,UO>%[V'QKJ/B;
M9J%V+"X^RM"89V1H<QY(4C[IR,'%`'/S_`62YF::;Q1)*['EY+8LQ^I+UU_@
M/P#+X*-QNUN>_CF4*L++MCCP<Y`R>:S/A]I!DOM8O9M4U2=].U*>UA2:\=TV
M`8&Y3P3SUKG_``;%=ZG;V5S=6GBNY=[DAKN+4,6^!(1G:6S@8YX[&@#O_%O@
M#0_&,0:^B:*Z082ZAX<#T/8CV->;S_`7589V.GZ_;E#WDC9&Q^&:T/%.HQ0>
M-]?;4Y?$365I#`R?V7.R)!E>2_(`R<<_6K&K/XI3X=^&T.I.FK7.H(L<PFR6
M5MY0.R\-QMSVH`J:1\`XDG636=9,T8.3%;1[=W_`C_A7JNE:38:)I\=AIMLE
MM;1#Y40=_4GN?<UQ'A3Q1+XC\=(Y>2$IHY6ZLRQQ#<++M;*^OOZ&L*U\<D_$
M!=8;6XVTZYOFTX6'G?<C``6;;GC+@\^E`'L%%>;>)?#RKX[T6TCU?6(X=6DN
M'N$2_=0-J[@%'\(R>E79KNXTCX@O:Q7%Q-;V?AUI%ADE+;V5^&/JQ`Z]:`,K
MQ)\'+GQ'K=QJ,_B><K*Y:..6'?Y2G^$?,.!]*W?!7P^;PK9WME=ZO)J=G=)L
M^S21[8T'.<`D]<USL.GW]S\/7\;/XDU)=7,#7BLMP1`N"?W?E]-N!BCQ#XDU
MV/7_``_K%AYC(FCB^O+)6.V6/(WX7U`;(^E`$4GP)6'4VN]+\1S6:ART($)+
MQCT#!A^==/XF^&6F>*-.M4O+F8:C;0K$-0`!>7`_C'1O7^M5O"WBB`V/BS79
M+Q[BPM[QI82SD@1^6I"KZ<GIZUD_#3Q-._B!]/O]9347U:V%\BK-O^S2Y.Z+
MKQ\N#CVH`R$^!.K+FW/B:-;4GE5B?G_@.<5Z)X-\!Z1X+MG%D&FNI1B6YEQN
M8>@]![5#X%N[J[N?$@N;B680ZQ+'&'8G8H`PH]![5U9.`2!DT`>:?'#6K&U\
M*1Z1*BRW=[(KQ#O&JGE_Z?B:S;&V/@SX106_^KO]9;S).S!6&?T3`_&LBX\$
M^+_%WQ`&H^(M-:UL?.!D=I%*1PJ<A5Y]/YDT[QIKXU[7&>`_Z';#RK<#I@=6
M_'^6*PKSY8>IWX"A[6LF]EJ<_7<?"B!W\27,X!V1VA5C[EEP/T/Y5P_2O:?A
M[H;:/X<229-MQ>'SG!'('\(_+G\:XL/'FFGV/;S*JH4&NKT.JHHHKU#Y4*@O
MK./4+"XLIBPBN(FB?:<'##!Q^=3T4`8=KX2TZSFT:6)I]VBP-!;9<8*LH4[N
M.3@4[0_"NF>'+S4+G34>,ZC*)98RWRJ1G[H[#DUM4F,T`<SX2?1%GU>WTR2X
M$\EX\]W%<##J[<$@?W>*KV/PZL]-1(K+7M=@A1]ZPQWN$R3D\8Z$U'XP\/WD
M5VGB70"4U&W'[V-1_KD^G<X[=Q6CX5\867B6W"@B"]0?O;=CS]5]1_*LE/7E
MEN=,Z*</:4]5U\BMJRZ-X=U:^U2_M;R6/5XTBNI`GF0HJ@J`0.1D&FZ1X;\.
MW6C:=::=J4MW::?=B[M@)PQC89PO3.WD\&NK=%D0HZAE88*D9!KE=2^'6BWD
MIN+,S:9<'G?:MM&?]W_#%5+F6JU(@J4E:5T^^_X%W_A#-*37-0UF`S6]WJ-N
M;>=HF`&#C+`8X;@<U%)X!\.R>&QH/V)5@6,()E51-P<[M^.N:Q)/!/BVW^6R
M\72L@Z"1G!_F:J2^!/&%Y\MWXD#+WS-(?TXJ'4E_*;K#TG_R]7W,WM>F\-Z9
M>Z7J.I:D[7>DHZP(L@9Y-R[3N4=3@>U84?C3P[=>*5UB+3]4FOWMOLBQ*JLK
M)NW?=SUS4EC\)+=7#ZAJDDOJL*;<_B<FNRTCP[I6A1[=/LTB8C!D/+M]6/-)
M>UD^R*DL)3C97D_N1SD'PWT>Y@4-)JMKI\K^<^D&ZQ`&)S@J.V>P.*Z-M`L6
MUR#5]K":"U:U1`1Y?ED@XQCVK3HK<X#E(OASH4&C7FD0FYCLKVZ%S+$L@QD$
M'8./N\#BM"\\(Z/=7EA>1VRVD]A-YL3VJK&3Q@JV!R".U;=%`'*-\/K,7UW=
MVNM:U9F\G:>6.VN]B%SU.,5U*C:H7).!C)ZFAW6-"[L%51DDG``KS;QC\1@Z
MR:=H4G7Y9+L?R3_'\JB=2,%=F]##SKRY8(?\1/&2A)-"TV7+'Y;J53T']P>_
MK^5>:4O4Y/7UK:\,>&+OQ+?^5$#';1D>=.1PH]!ZGVKS)2E5D?44J=+"4M]%
MNS1\!>%FU[5!=W,?^@VK`MD<2/V7^IKV<#`Q573=.M=*L(K*SB$<,0PH]?<^
MI-6A7HTJ:IQL?-XO$O$5.;IT"BBBM3D"BBB@`HHHH`*X?Q9X#-Y<'5]"?[+J
M"'>R*VT2'U![-^AKN**B4%)69K2JSI2YH,\TT;XDW6G3G3_$UK(LD9VM,J8=
M?]Y>_P!17?Z=JUAJT`FL+N*X3_8;)'U'454UWPSI?B&'9?6X,@'R3)PZ?0_T
M-><ZI\/->T.<W6CSO=(O(:%MDJ_AW_"L6ZE/S1VJ.&Q&SY)?@>NT5XS:?$/Q
M/I4GD7;K<%."EU%A_P`Q@UO6OQ=3`%YH[@]S#,"/R(IK$4WOH*>6XB.ROZ,]
M(HKB(_BMH3#]Y;7L9_ZY@_UIY^*GAT#A+T_]L1_C5^VI]S#ZGB/Y&=I17`3_
M`!;TU1_H^F74I[;V5/\`&L:]^*^JS`K9V-O;#LSDR'^@J7B*:ZFD,OQ,OLV/
M5R0`2>`.YKF=<\?Z)HP:-9_MER/^64!S@^[=!7D^I^)-:UC(OM1FD0_\LU.U
M/R'%98'10.3T`K">*?V4>A1RE+6K+[C?\1>,M5\1$QS2>1:YXMXCA3_O'^*L
M#@5T.C>!M>UDJR6AMH#_`,MKCY1CV'4UZ+X?^'FDZ,5GN!]NNEY#RK\JGV7_
M`!S64:52J[LZZF+PV%CR0^Y'#^%O`%]KK)<WH>SL>NXC#RC_`&1V'N:];T_3
MK32[*.SLH5AAC&`J_P`SZGWJR*6NZG2C36AX.)Q=3$/WMNP4"B@5J<@44M%`
M"44M%`"44M%`"44M%`"48I:*`*=_I.GZI'LOK.&X'_31`2/H>U<Q??"[0+DE
MK<W%FQ_YYR;E_)LUV=%1*$9;HVIUZM/X)-'F-Q\(I03]EUA2.PEAQ^H-53\)
M=6SQJ5F?P?\`PKUBBLWAZ;Z'4LRQ*^U^"/)_^%2ZM_T$;+\G_P`*F@^$5X3_
M`*1J\*C_`*9PD_S(KU*BE]6I]@>98E]?P1PMG\)]'A(-W=W5T1V!"#].?UKI
M=-\,Z-I.#9:=!$P_CV[F_,\UJT5K&G".R.:IB:U3XI-B8HI:*LP$HI:*`$HI
%:*`/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
